Research programme: antibody-based cancer therapeutics - MabSpace BiosciencesAlternative Names: MSB 2311
Latest Information Update: 07 Mar 2017
At a glance
- Originator MabSpace Biosciences
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 Mar 2017 Research programme: antibody-based cancer therapeutics - MabSpace Biosciences is available for licensing in (excluding China) as of 23 Feb 2017.
- 23 Feb 2017 MabSpace intends to file an IND application with the CFDA in China for Cancers
- 23 Feb 2017 MabSpace plans a first in-human trial for Cancer in China